Conjugate vaccines are used in preventing the diseases by invoking an immune response to an antigen, the external part of a bacteria or virus that the immune system recognizes. The treatment is usually accomplished with an attenuated or dead version of a pathogenic bacterium or virus in the vaccine so that the immune system can detect the antigen later in life. The Conjugate vaccines are used for treating Hepatitis B, Hib (Haemophilus influenza type b) disease, diphtheria tetanus pertussis (DTP), Meningococcal disease, HPV (Human papillomavirus), Pneumococcal disease, Whooping cough, and Shingles. These vaccines have innovative arrangements of adding the immune system which is used broadly to produce protection besides conquering pathogens or to create specific antibodies against a goal molecule.
Conjugate vaccines are defined by two type monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent vaccines aimed to vaccinate against a single microorganism or single antigen while multivalent conjugate vaccines vaccinate against two or more draining of the same viruses.
According to study, “Latin America Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently working in the Latin America conjugate vaccine market are Pfizer Inc., Sanofi Pasteur, Merck & Co., CSL Limited, Novartis. All these vendors launching new products in the market owing to rising research & development (R&D) spending and violent strategies.
Based on the application, the conjugate vaccine is segmented into the academic institute, research institute, pharmaceuticals industries, and others. The major benefits are the ability to elicit immunological memory, reduce asymptomatic carriage of the bacteria, longer fixed protection, the establishment of herd insusceptibility, more durable immunity, low cost, easy transportation. In addition, some of the major disadvantages include no local immunity, obsessiveness, and loss of hungriness etc.
The Brazilian National Immunization Program (NIP) is a government authority, which is responsible for arranging distinct sector vaccination activities formerly organized in remote programs of infection control. NIP offers several conjugate vaccines such as Pneumococcal 10-valent conjugate vaccine (PCV10), Hib and other vaccines.
The Latin America vaccine market is generally driven by increasing chronic diseases, growing exertions for the acceptance of suitable preventive broadcast methods, enhancement in patient acquiescence along with an accumulative product pipeline, longer immunity and need of better safety of vaccines, widespread routine vaccination programs, rising adoption of cancer therapeutic vaccines, control strategies and government initiatives. In addition, some of the major drawbacks are low accessibility, complex manufacturing procedure, limited awareness of Hib disease, malpractices by top vaccine manufacturers, recent incidents of frauds, slow introduction in low-income countries, low penetration rate, emerging companies, the situation of oligopoly, pricing inefficiencies and the complicated manufacturing processes and others. Additionally, some of the new opportunities associated with the conjugate vaccine market are raising investment in developing countries.
It is estimated that the conjugate vaccine market in Latin America to reach at USD 5.4 billion, at a CAGR of 20.4 %, by 2023. In terms of volume, it is expected that market to reach by 839.2million units, expanding at a CAGR of 20.1%. In the coming years, it is predicted that the market grows progressively due to rising technological advancements.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications